Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE TrialXi Li, Li Zhang, Da Jiang, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)Yunpeng Yang, Ting Zhou, Xiaozhong Chen, et al.
Journal of Medicinal Chemistry|April 6, 2021
Structure-Based Design of Selective LONP1 Inhibitors for Probing <i>In Vitro</i> BiologyLaura J Kingsley, Xiaohui He, Matthew McNeill, et al.
Theranostics|June 3, 2020
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patientsQiaoyun Tan, Dan Wang, Jianliang Yang, et al.
Cancer Science|October 11, 2018
Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failureShaoxuan Hu, Yuqin Song, Xiuhua Sun, et al.
Cancer Cell|May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Yunpeng Yang, Jianji Pan, Hui Wang, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory DiseasesXiaohui He, Sara Da Ros, John Nelson, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2023
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid CancerYansong Lin, Shukui Qin, Hui Yang, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Pageof 20